Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 3
Volume 3 CME Connect The Journal SPECIALTY SITES Pathology & OTHER SITES Today CME Your 2008 CME Credits: Return to Pathology & More: -- Volume 3 CME Release

interTrend Partners With The San Francisco Hep B Free Campaign to Increase Awareness and Understanding of Hepatitis B
- The 'B a Hero' Campaign Will Be Launched in August - LONG BEACH, Calif., Aug. 28 /PRNewswire/ -- interTrend Communications, a full-service Asian American marketing communications agency, joined forces with The SF Hep B Free Campaign (The SF Hep B Free)

[Original articles] Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection
Extract not available.

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

Int J Clin Lab Res 1998;28(2):96-99

Hepatitis C virus genotypes and clinical features in hepatitis C virus-related mixed cryoglobulinemia.

Origgi L, Vanoli M, Lunghi G, Carbone A, Grasso M, Scorza R

Terza Divisione di Medicina Interna, IRCCS Ospedale Maggiore, Milan, Italy.

Mixed cryoglobulinemia is a systemic disease, almost always associated with hepatitis C virus infection and characterized by purpura and cutaneous vasculitis, asthenia, arthralgias, and often renal and neurological involvement. No significant differences have been described to date in mixed cryoglobulinemia patients with type 1, 2, or 3 hepatitis C virus infection with respect to symptoms, while a higher prevalence of genotype 2a has been reported in patients without clinical and biochemical signs of liver disease or with serum autoantibodies. We examined 33 hepatitis C virus-positive patients with mixed cryoglobulinemia to assess if any clinical or serological feature is related to infection with different genotypes. All subjects underwent viral genotype determination by means of a single-step polymerase chain reaction. Thirteen patients (39%) were infected with hepatitis C virus type 1b, 17 (52%) with type 2a or 2a/c, and 3 (9%) with type 3. There was a significant difference in the frequency of peripheral nervous system involvement: paresthesias or other symptoms of peripheral neuropathy were less frequent in patients with 2a or 2a/c infection (29%) than in patients with type 1b or type 3 infection (88%, P = 0.003). Only patients with hepatitis C virus type 2 had urticaria or cutaneous ulcers. These patients also had a lower frequency of arthralgias, lower cryocrit values (P = 0.02), and lower serum levels of alanine-aminotransferase and gamma-glutamyl-transpeptidase (P < 0.04) than patients with type 1 and type 3 infection. The prevalence of antinuclear antibody positivity was similar in the three groups.

PMID: 9689550, UI: 98353975

table of Contents

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 29 Aug 2008